GlassScriptPhysician profile
Glen J Dasher
NPI 1972684546
$11,117.01
in general payments reported to CMS, 2019-2025
73 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $1,590 · 2021: $1,863 · 2022: $1,775 · 2023: $1,808 · 2024: $1,475 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,788.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,339.38 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,036.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $947.48 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $586.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $559.95 | 2019-2025 | Airsupra, Farxiga, Evusheld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.73 | 2019-2022 | |
| Pfizer INC. | $496.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $379.93 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $344.68 | 2019-2025 | |
| Astellas Pharma US INC | $308.25 | 2020-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.73 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $276.30 | 2019-2023 | |
| Glaxosmithkline, LLC. | $242.44 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $217.10 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $176.17 | 2023-2024 | Gemtesa, Aptiom |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Dasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.